A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 396 participants.
Also called NCT06857955
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose other
- Phase
- Phase 2
- Enrolled
- 396 participants
- Sponsor
- Registry
-
NCT06857955
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States, Japan, Singapore
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06857955. Randomized; triple masking; primary purpose other. Start 2025-03-26 (actual); primary completion 2026-09-17 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
- Condition
- Hypertension
- Intervention (Other)
- Saline
- Intervention (Drug)
- QCZ484
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct06857955- Content hash
de8f19443841a4aa1ce273372c4484fc114f1de11aac6d627c885953c5e22b87